AI-driven neoantigen selection
Integrates genomic, transcriptomic, and proteomic data with proprietary AI models to pinpoint neoantigens that elicit potent anti-tumor immune responses.
Neoantigen Precision Discovery PlatformLearn moreIndividualized immunotherapy
Individualized Precision Combination Immunotherapy Against Solid Tumors
Perfecting tumor neoantigen mapping, mRNA-DC vaccination and cellular therapy to pioneer next-generation individualized cancer treatment.
Peptide synthesis
Analytical QC
Cell processing
Controlled facility
R&D and process development at our Guangzhou facilities — investigational programs, not a marketed product.
Technology Pipeline
Technological Hallmarks
Tvac® is a personalized precision tumor immunotherapy integrating neoantigen vaccine active immunization and neoantigen-reactive T cell passive immunization.
It features precise tumor targeting with superior safety, overcoming tumor heterogeneity and immune escape for synergistic anti-tumor effects. The therapy delivers fast efficacy and long-term immune memory to reduce recurrence risk, and remodels cold tumors into hot tumors to enhance immunotherapy response. With personalized and modular design, Tvac® supports standardized processes and reliable clinical translation.
Core Advantages
- Precise targeting & high safety
- Rapid and long-lasting efficacy
- Efficient transformation of cold tumors to hot tumors
- Personalized & modular design
mRNA-DC vaccination
Advances peptide and mRNA-DC neoantigen vaccines through modular, standardized workflows—combining mature peptide approaches with efficient dendritic-cell loading for broad, safe coverage.
Vaccine Technology PlatformLearn more
Potent tumor neoantigen-reactive T-cell killing
Enriches and expands neoantigen-reactive T cells (NRTs) from patient PBMCs for adoptive transfer, delivering targeted cytotoxicity with a short preparation cycle.
Cell Therapy PlatformLearn moreThis website is informational and does not constitute medical advice or an offer of therapy.
Tvac®
Personalized precision tumor immunotherapy
Tvac® is a personalized precision tumor immunotherapy strategy developed from each patient’s tumor neoantigen profile. It integrates passive immunization (neoantigen-reactive T-cell adoptive therapy) with active immunization (neoantigen vaccine) in one coordinated regimen.
Engineered for high precision and favorable safety, Tvac® targets tumor-specific neoantigens with extremely low off-target toxicity and no damage to normal tissues. It addresses tumor heterogeneity and immune escape through polyclonal neoantigen coverage and T cells directed at dominant high-frequency clones—delivering multi-target, synergistic anti-tumor activity.
Adoptively transferred T cells can eliminate tumor lesions rapidly, while neoantigen vaccines establish long-term immune memory to reduce recurrence risk. The platform can remodel immunosuppressive “cold tumors” into immune-activated “hot tumors”, improve lymphocyte infiltration, and enhance outcomes in immunotherapy-insensitive disease. Vaccine and T-cell regimens are designed in parallel from the same neoantigen spectrum—supporting modular, standardized workflows and clinical translation.
Core Advantages
High targeting specificity and favorable safety profile
Specifically targeting only tumor neoantigens with extremely low off-target toxicity and no damage to normal tissues.
Rapid onset and durable therapeutic efficacy
Adoptively transferred T cells eliminate tumor lesions rapidly, while neoantigen vaccines establish long-term immune memory to reduce recurrence risk.
Efficiently remodels cold tumors into hot tumors
Activates the local tumor immune microenvironment, elevates lymphocyte infiltration, and improves outcomes in immunotherapy-insensitive tumors.
Highly personalized and modular design
Synchronous design of vaccine and T cell regimens based on the same neoantigen spectrum, with a workflow amenable to standardization.
Our Platforms
Leveraging our proprietary high-performance computing clusters and bioinformatic platform, we have developed an advanced neoantigen prediction system. By integrating multi-omic data across genomic, transcriptomic, and proteomic dimensions, the platform enables comprehensive detection of tumor-specific mutations from DNA to protein levels. Our high-dimensional evaluation models extract intricate features to accurately identify neoantigens capable of triggering potent anti-tumor immune responses, ensuring unmatched reliability and precision for personalized immunotherapy.
Multi-omic Integration & Proprietary Analytical PlatformAI Predictive Modeling & Immunological Evaluation
Scientific context
Clinical research experience
Tvac has been explored in clinical research at multiple Grade A tertiary hospitals in Guangdong, with experimental treatment in more than 100 patients with advanced tumors. Analyses report induction of tumor-specific immune cells and survival-related outcomes.
Published peer-reviewed literature.
Ruan QZ, Fu JQ, Wu XX, Huang LP, Ruan RS. Rational combinations of in vivo cancer antigen priming and adoptive T-cell therapy mobilize immune and clinical responses in terminal cancers. Cancer Immunol Immunother. 2018 Jun;67(6):907-915. doi: 10.1007/s00262-018-2142-z. Epub 2018 Mar 6. PMID: 29511794; PMCID: PMC11028218. https://pubmed.ncbi.nlm.nih.gov/29511794/
Sequential combination strategies targeting tumor immune negative-feedback mechanisms remain an area of ongoing research.
Note: Historical cohorts and published priming approaches are not equivalent to current neoantigen mRNA-DC / NRT product candidates.
Informational content only. Investigational approaches require appropriate regulatory review and controlled clinical evidence before clinical claims can be established.
About Us
About Us
Born from the belief that cancer care should be as targeted as the disease itself, we develop Tvac and companion innovations for patients worldwide.
Our Mission
To revolutionize cancer treatment through innovative medical technology, making advanced therapy accessible and effective for patients worldwide.
Our Vision
To be the global leader in targeted vacuum-assisted chemotherapy (Tvac), setting new standards for precision oncology and patient care.
Our Values
- Innovation
- We push the boundaries of what's possible in medical science.
- Precision
- Every detail matters in the fight against cancer.
- Compassion
- Patients are at the heart of everything we do.
- Integrity
- We uphold the highest ethical standards in research and clinical practice.
Our Story
Founded by a team of visionary oncologists and engineers, RCMT was born from a simple yet powerful idea: that cancer treatment should be as targeted as the disease itself. Our journey began with the development of Tvac technology, a breakthrough in localized chemotherapy delivery. Today, we continue to innovate, driven by the success stories of our patients and the potential to save countless lives.
- Founded
- 2019
- Headquarters
- Guangzhou, China
Leadership & team
Credentials and expertise across translational oncology, clinical development, CMC, and quality.
Runsheng Ruan, PhD
Founder & Chairman
Expertise
- Tumor Immunology
- Translational Oncology
- Strategic Scientific Leadership
Dr. Ruan holds a Ph.D. in Medicine from the University of Zurich and previously served as a Senior Research Fellow at the National University of Singapore. With over 30 years of experience in tumor immunology research and development, he has led multiple pioneering programs in cancer immunotherapy. His work focuses on bridging fundamental science with clinical translation, providing the scientific foundation and strategic direction for the company’s innovation pipeline.
Qingzhao Ruan, MD
Chief Executive Officer (CEO)
Expertise
- Clinical Translation
- Interventional Pain Medicine
- International Medical Strategy
Dr. Ruan trained at UCL Medical School (UK) and completed advanced clinical training across Harvard Medical School and Weill Cornell Medicine in the United States. He is a board-certified specialist in Anesthesiology and Pain Medicine, with extensive experience in neuromodulation and complex patient care. With over 40 peer-reviewed SCI publications, he brings a unique combination of clinical excellence, academic productivity, and global healthcare perspective to lead the company’s translational and clinical strategy.
Boyue Zhang, PhD
Technical Director
Expertise
- mRNA Vaccine Development
- Tumor Immunology
- Process Development
Dr. Zhang earned his Ph.D. from South China Agricultural University and has over a decade of experience in tumor immunology and mRNA vaccine research. He has led the development and optimization of multiple innovative pipelines, with a focus on scalable manufacturing processes and clinical translation of mRNA-based therapeutics.
Jing Pan
Deputy General Manager
Expertise
- Operations Management
- Regulatory Compliance
- Corporate Governance
Ms. Pan holds a Master’s degree from Southwest University of Political Science and Law and brings over 20 years of management experience in the biopharmaceutical industry. As an early member of the company, she oversees corporate operations, compliance systems, and organizational development, ensuring efficient and compliant execution of business strategy.
Guozheng Liang, MSc
Project Lead, R&D
Expertise
- Neoantigen Discovery
- mRNA-DC Vaccines
- Gene Editing
Mr. Liang holds a Master’s degree in Medicine from Guangdong Pharmaceutical University. His research background includes CRISPR/Cas9-based tumor cell engineering. He currently focuses on the identification of personalized tumor neoantigens and the development of neoantigen-loaded mRNA dendritic cell (DC) vaccines, contributing to next-generation individualized immunotherapy platforms.
Xiaomei Lu, MSc
Head of Quality Systems
Expertise
- ATMP Quality Management
- GMP Systems
- Lifecycle Quality Control
Ms. Lu holds a Master’s degree in Translational Medicine from Guangxi Medical University and has over 5 years of experience in quality management within Advanced Therapy Medicinal Products (ATMPs). She is responsible for end-to-end quality systems across multiple pipelines, ensuring compliance, consistency, and regulatory readiness throughout the product lifecycle.
Wenkeng Chen
Clinical Affairs Manager
Expertise
- Clinical Development
- Academic Engagement
- Hospital Partnerships
Mr. Chen graduated in Clinical Medicine from Southern Medical University and has more than 10 years of experience in clinical development and academic program management within the biopharmaceutical sector. His expertise spans full-cycle clinical trial coordination, hospital collaboration, and translation of scientific outcomes into clinical practice.
Muchun Zhu, MSc
Head of Bioinformatics Platform
Expertise
- Neoantigen Prediction
- Multi-omics Integration
- Cancer Bioinformatics
Mr. Zhu holds a Master’s degree in Bioinformatics and specializes in large-scale multi-omics data analysis in oncology. His work integrates genomics, transcriptomics, and immunomics to support neoantigen discovery and precision immunotherapy. He has published multiple SCI-indexed papers and holds several invention patents.
Lichang Lai, MSc
GMP Operations Manager
Expertise
- GMP Compliance
- Cell Therapy Manufacturing
- Quality Traceability
Ms. Lai holds a Master’s degree in Medicine from Guangzhou University of Chinese Medicine. She has extensive experience in tumor immunotherapy development and clinical translation, with particular expertise in GMP facility setup, batch record systems, and full-process material traceability for cell-based therapies.
News
News
Selected updates aligned with our pipeline and publications.
Company news · 2025-11-24
Innovative immunotherapy pathway: building an mRNA-DC–mediated neoantigen NRT response platform
Runsheng Cell reports AI neoantigen prediction, patent cluster, completed preclinical work, and pilot-scale process toward IND-oriented development.
Read moreCompany news · 2025-10-31
Runsheng Cell founder Ruan Runsheng at IGC 2025 on individualized precision immunotherapy
At IGC 2025 in Guangzhou, founder Professor Ruan Runsheng joined a roundtable on solid tumors and autoimmune disease and presented first IIT data for TVAC001 neoantigen vaccine plus reactive T cells.
Read moreScience · 2025-10-30
Research advance in tumour vaccines — shared neoantigen discovery in advanced NSCLC at ASCO 2025
Whole-exome plus transcriptome profiling and neoantigen prediction identified candidate shared neoantigens in advanced NSCLC; results presented at ASCO 2025.
Read moreCompany news · 2025-10-29
One year of personalised neoantigen vaccine plus cell therapy IIT: early signs of disease control
The IIT at Sun Yat-sen University Cancer Center completed one year; five patients enrolled so far, with stable disease signals and no grade 3+ adverse events in the reporting period.
Read moreScience · 2025-09-23
Neoantigen prediction as the navigation layer for precision immunotherapy
Runsheng Cell outlines a multi-omics + AI neoantigen prediction stack, performance claims, and patent filings supporting individualized vaccine development.
Read moreScience · 2025-06-10
A new path in cancer immunotherapy — neoantigen mRNA–DC vaccine plus neoantigen-reactive T cells
Runsheng Cell research describes Neo-DC vaccination combined with neoantigen-reactive T cells (NRT) to strengthen immune responses in solid tumor models.
Read moreCompany news · 2025-01-15
RCMT advances Tvac001 clinical preparation for solid tumors
The team is accelerating clinical preparation for Tvac001, an individualized neoantigen vaccine approach for advanced solid tumors.
Read more
Clinical Studies
Clinical Studies
Clinical Research Pipeline: Tvac® Individualized Precision Combination Immunotherapy
Indications
Patients aged 18 years or older with histologically or cytologically confirmed solid tumors, including but not limited to liver cancer, lung cancer, gastric cancer, colorectal cancer, uterine tumors, pancreatic cancer, breast cancer, ovarian cancer, melanoma, sarcomas (Ewing sarcoma, leiomyosarcoma, osteosarcoma), etc. Eligible for patients who have failed standard treatment, have no available standard treatment regimens, or are not eligible for standard treatment at the current stage.
Clinical Progress
Lead product Tvac001 is in clinical research in collaboration with Sun Yat-sen University Cancer Center, with multiple patients enrolled. To date, no Grade 2 or above adverse events have been observed, and the Objective Response Rate (ORR) has reached 80%, preliminarily verifying the safety and efficacy of the treatment regimen.
Collaborating Institution
In-depth scientific research collaboration with multiple departments of Sun Yat-sen University Cancer Center, implementing multidisciplinary joint diagnosis and treatment. As one of China's top cancer hospitals, it ranks 4th among global specialized cancer institutions in the 2025 Nature Index.
Clinical research inquiries
For questions about investigational clinical research (not emergency care), contact our team: info@gzrcmt.com. We typically respond within 3 business days.
Investigational program; outcomes described are preliminary and not a substitute for controlled clinical trials or regulatory review.
Contact
Contact
For business development, collaborations, and media, please reach out by phone or email.
Contact number
(020) 3685 8614Company email
info@gzrcmt.comHeadquarters address
5th Floor, Building 9 (Building 6#), No. 6, Nanjiang 2nd Road, Zhujiang Street, Nansha District, Guangzhou
Medical & forward-looking information
Information on this site is for general informational purposes only and is not medical advice. Product candidates are under development; regulatory approval and clinical outcomes are uncertain. Past performance in research does not guarantee future results.